QIU Meng, Literature Co-worker: YANG Dong-yang. Comparison of Efficacy and Safety of Pembrolizumab Versus Standard Therapy in the First-Line Treatment of Patients With MSI-H / dMMR Metastatic Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(4): 227-231. DOI: 10.12019/j.issn.1671-5144.2020.04.007
|
Citation:
|
QIU Meng, Literature Co-worker: YANG Dong-yang. Comparison of Efficacy and Safety of Pembrolizumab Versus Standard Therapy in the First-Line Treatment of Patients With MSI-H / dMMR Metastatic Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(4): 227-231. DOI: 10.12019/j.issn.1671-5144.2020.04.007
|
QIU Meng, Literature Co-worker: YANG Dong-yang. Comparison of Efficacy and Safety of Pembrolizumab Versus Standard Therapy in the First-Line Treatment of Patients With MSI-H / dMMR Metastatic Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(4): 227-231. DOI: 10.12019/j.issn.1671-5144.2020.04.007
|
Citation:
|
QIU Meng, Literature Co-worker: YANG Dong-yang. Comparison of Efficacy and Safety of Pembrolizumab Versus Standard Therapy in the First-Line Treatment of Patients With MSI-H / dMMR Metastatic Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(4): 227-231. DOI: 10.12019/j.issn.1671-5144.2020.04.007
|
DownLoad: